This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CD74 antibody-drug conjugate (ADC)
Description: HuMax-CD74 is an antibody-drug conjugate (ADC) targeted to CD74, a membrane-associated protein with a role in antigen presentation by B cells and other antigen presenting cells.
Deal Structure: In April 2011, Genmab and Seattle Genetics announced that the companies entered into an antibody-drug conjugate (ADC) research collaboration agreement. Under the new agreement, Genmab has rights to utilize Seattle Genetics ADC technology with HuMax-CD74, an antibody in pre-clinical development to target CD74, which is expressed on a wide range of hematological malignancies and solid tumors. Seattle Genetics received an undisclosed upfront payment and has the right to exercise a co-development and co-commercialization option for any resulting ADC products at the end of Phase I clinical development.
Genmab is responsible for research, manufacturing, pre-clinical development and Phase I clinical evaluation of ADCs under this new collaboration. Seattle Genetics will receive research support payments for any assistance provided to Genmab. If Seattle Genetics opts into an ADC product at the end of Phase I, a payment would be due to Genmab and the companies would co-develop and share all...See full deal structure in Biomedtracker
Partners: Seattle Genetics, Inc.
HuMax-CD74 ADC News
Additional information available to subscribers only: